227 related articles for article (PubMed ID: 21993874)
1. Antibody therapy for Adult T-cell leukemia-lymphoma.
Ishida T; Ueda R
Int J Hematol; 2011 Nov; 94(5):443-52. PubMed ID: 21993874
[TBL] [Abstract][Full Text] [Related]
2. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.
Ishii T; Ishida T; Utsunomiya A; Inagaki A; Yano H; Komatsu H; Iida S; Imada K; Uchiyama T; Akinaga S; Shitara K; Ueda R
Clin Cancer Res; 2010 Mar; 16(5):1520-31. PubMed ID: 20160057
[TBL] [Abstract][Full Text] [Related]
3. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.
Ishida T; Joh T; Uike N; Yamamoto K; Utsunomiya A; Yoshida S; Saburi Y; Miyamoto T; Takemoto S; Suzushima H; Tsukasaki K; Nosaka K; Fujiwara H; Ishitsuka K; Inagaki H; Ogura M; Akinaga S; Tomonaga M; Tobinai K; Ueda R
J Clin Oncol; 2012 Mar; 30(8):837-42. PubMed ID: 22312108
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
[TBL] [Abstract][Full Text] [Related]
5. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
Winsett FT; Lewis DJ; Duvic M
Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
[TBL] [Abstract][Full Text] [Related]
6. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas.
Tobinai K; Takahashi T; Akinaga S
Curr Hematol Malig Rep; 2012 Sep; 7(3):235-40. PubMed ID: 22538464
[TBL] [Abstract][Full Text] [Related]
7. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma.
de Lartigue J
Drugs Today (Barc); 2012 Oct; 48(10):655-60. PubMed ID: 23110261
[TBL] [Abstract][Full Text] [Related]
8. Galectin-9 as a Predictive Marker for the Onset of Immune-Related Adverse Effects Associated with Anti-CCR4 MoAb Therapy in Patients with Adult T Cell Leukemia.
Mohammed TO; Chagan-Yasutan H; Ashino Y; Nakayama W; Takahashi Y; Shimomura T; Fujimoto T; Watanabe Y; Niki T; Suzushima H; Hattori T
Tohoku J Exp Med; 2017 Mar; 241(3):201-208. PubMed ID: 28321034
[TBL] [Abstract][Full Text] [Related]
9. [Development of an anti-CCR4 antibody, mogamulizumab, the first approved antibody made by POTELLIGENT(®) technology].
Ishii T
Nihon Yakurigaku Zasshi; 2013 Oct; 142(4):167-71. PubMed ID: 24107520
[No Abstract] [Full Text] [Related]
10. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
11. Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.
Antoniu SA
Curr Opin Mol Ther; 2010 Dec; 12(6):770-9. PubMed ID: 21154168
[TBL] [Abstract][Full Text] [Related]
12. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.
Remer M; Al-Shamkhani A; Glennie M; Johnson P
Immunotherapy; 2014; 6(11):1187-206. PubMed ID: 25496334
[TBL] [Abstract][Full Text] [Related]
13. Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia.
Tanaka H; Fujiwara H; Ochi F; Tanimoto K; Casey N; Okamoto S; Mineno J; Kuzushima K; Shiku H; Sugiyama T; Barrett AJ; Yasukawa M
Clin Cancer Res; 2016 Sep; 22(17):4405-16. PubMed ID: 27091408
[TBL] [Abstract][Full Text] [Related]
14. Clinical Application of Anti-CCR4 Monoclonal Antibody.
Ueda R
Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
[TBL] [Abstract][Full Text] [Related]
15. CCR4 is rarely expressed in CCR4-mutated T/NK-cell lymphomas other than adult T-cell leukemia/lymphoma.
Sakamoto Y; Fujii K; Murase S; Nakano S; Masaki A; Murase T; Kusumoto S; Iida S; Utsunomiya A; Ueda R; Ishida T; Inagaki H
Int J Hematol; 2019 Oct; 110(4):389-392. PubMed ID: 31468320
[TBL] [Abstract][Full Text] [Related]
16. Mogamulizumab for the treatment of T-cell lymphoma.
Makita S; Tobinai K
Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the treatment of adult T-cell leukemia-lymphomas.
Utsunomiya A; Choi I; Chihara D; Seto M
Cancer Sci; 2015 Apr; 106(4):344-51. PubMed ID: 25613789
[TBL] [Abstract][Full Text] [Related]
18. Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
Ureshino H; Kamachi K; Kimura S
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):326-331. PubMed ID: 30981611
[TBL] [Abstract][Full Text] [Related]
19. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
[TBL] [Abstract][Full Text] [Related]
20. CCR4 and its ligands: from bench to bedside.
Yoshie O; Matsushima K
Int Immunol; 2015 Jan; 27(1):11-20. PubMed ID: 25087232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]